4 results on '"John D. Burkhardt"'
Search Results
2. Impact of digital monitoring on compliance and outcome of lifestyle-change measures in patients with coexistent atrial fibrillation and obesity
- Author
-
Sanghamitra Mohanty, MD, FHRS, Chintan Trivedi, MD, MPH, FHRS, Domenico Giovanni Della Rocca, MD, Carola Gianni, MD, Bryan MacDonald, MD, Angel Mayedo, MD, SaiShishir Shetty, DPharm, MHI, Eleanora Natale, HSGrad, John D. Burkhardt, MD, FHRS, Mohamed Bassiouny, MD, G. Joseph Gallinghouse, MD, Rodney Horton, MD, Amin Al-Ahmad, MD, FHRS, and Andrea Natale, MD, FACC, FHRS, FESC
- Subjects
Digital monitoring ,App ,Lifestyle change ,Weight loss ,Atrial fibrillation ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Medical technology ,R855-855.5 - Abstract
Introduction: Obesity, a known risk factor for atrial fibrillation (AF), is potentially reversible through lifestyle changes, including diet and physical activity. However, lack of compliance is a major obstacle in attaining sustained weight loss. We investigated the impact of patient engagement using a digital monitoring system on compliance for lifestyle-change measures and subsequent outcome. Methods: A total of 105 consecutive patients with coexistent AF and obesity (body mass index ≥28) were classified into 2 groups based on the monitoring method: group 1, use of digital platform (n = 20); group 2, conventional method (n = 85). Group 1 used the RFMx digital monitoring platform (smartphone app) that sets weekly goals for exercise and weight loss, tracks patient compliance data continuously, and sends regular text reminders. Conventional method included monitoring patients’ adherence to diet and change in weight during in-person clinic visits or monthly phone calls from staff. Results: Baseline characteristics of groups 1 and 2 were comparable. At 6 months of follow-up, 12 (60%) and 28 (33%) from group 1 and 2, respectively, were compliant with the physician instructions regarding diet and exercise (P = .025). Weight loss was observed in 9 of 12 (75%) from group 1 and 11 of 28 (39%) from group 2 (P = .038) and mean reduction in weight was 9.9 ± 8.9 lb and 4.0 ± 2.1 lb (P = .042). Conclusion: In this series, continuous digital monitoring was seen to be associated with significant improvement in compliance through better patient engagement, resulting in more weight loss compared to the conventional method.
- Published
- 2022
- Full Text
- View/download PDF
3. Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation
- Author
-
Sanghamitra Mohanty, Prasant Mohanty, Chintan Trivedi, Joanna Assadourian, Angel Quintero Mayedo, Bryan MacDonald, Domenico G. Della Rocca, Carola Gianni, Rodney Horton, Amin Al‐Ahmad, Mohamed Bassiouny, John D. Burkhardt, Luigi Di Biase, M. Edip Gurol, and Andrea Natale
- Subjects
AFEQT ,atrial fibrillation (AF) ,cognition ,left atrial appendage occlusion (LAAO) ,MoCA ,oral anticoagulation (OAC) ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background We compared the cognitive status and quality of life in patients with atrial fibrillation undergoing left atrial appendage occlusion (LAAO) or remaining on oral anticoagulation (OAC) after atrial fibrillation ablation. Methods and Results Cognition was assessed by the Montreal Cognitive Assessment (MoCA) survey at baseline and follow‐up. Consecutive patients receiving LAAO or OAC after atrial fibrillation ablation were screened, and patients with a score of ≤17 were excluded from the study. Quality of life was measured at baseline and 1 year using the Atrial Fibrillation Effect on Quality of Life survey. A total of 50 patients (CHA2DS2‐VASc [congestive heart failure, hypertension, age≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65–74 years, sex category] score: 3.30±1.43) in the LAAO group and 48 (CHA2DS2‐VASc score 2.73±1.25) in the OAC group were included in this prospective study. Mean baseline MoCA score was 26.18 and 26.08 in the LAAO and OAC groups, respectively (P=0.846). At 1 year, scores were 26.94 and 23.38 in the respective groups. MoCA score decreased by an estimated −2.74 (95% CI, −3.61 to −1.87; P
- Published
- 2021
- Full Text
- View/download PDF
4. Catheter Ablation for Atrial Fibrillation in Adult Congenital Heart Disease
- Author
-
Jack R. Griffiths, Udi Nussinovitch, Jackson J. Liang, Richard Sims, Zachary T. Yoneda, Hannah M. Bernstein, Mohan N. Viswanathan, Paul Khairy, Uma N. Srivatsa, David S. Frankel, Francis E. Marchlinski, Amneet Sandhu, M. Benjamin Shoemaker, Sanghamitra Mohanty, John D. Burkhardt, Andrea Natale, Dhanunjaya Lakireddy, Natasja M.S. De Groot, Edward P. Gerstenfeld, Jeremy P. Moore, Pablo Ávila, Sabine Ernst, Duy T. Nguyen, and Cardiology
- Subjects
Adult ,Heart Defects, Congenital ,Male ,Transposition of Great Vessels ,Middle Aged ,Treatment Outcome ,Pulmonary Veins ,Physiology (medical) ,Atrial Fibrillation ,Catheter Ablation ,Humans ,Female ,Registries ,Cardiology and Cardiovascular Medicine ,Child ,Anti-Arrhythmia Agents ,Aged ,Retrospective Studies - Abstract
Background: Data on atrial fibrillation (AF) ablation and outcomes are limited in patients with congenital heart disease (CHD). We aimed to investigate the characteristics of patients with CHD presenting for AF ablation and their outcomes. Methods: A multicenter, retrospective analysis was performed of patients with CHD undergoing AF ablation between 2004 and 2020 at 13 participating centers. The severity of CHD was classified using 2014 Pediatric and Congenital Electrophysiology Society/Heart Rhythm Society guidelines. Clinical data were collected. One-year complete procedural success was defined as freedom from atrial tachycardia or AF in the absence of antiarrhythmic drugs or including previously failed antiarrhythmic drugs (partial success). Results: Of 240 patients, 127 (53.4%) had persistent AF, 62.5% were male, and mean age was 55.2±13.3 years. CHD complexity categories included 147 (61.3%) simple, 68 (28.3%) intermediate, and 25 (10.4%) severe. The most common CHD type was atrial septal defect (n=78). More complex CHD conditions included transposition of the great arteries (n=14), anomalous pulmonary veins (n=13), tetralogy of Fallot (n=8), cor triatriatum (n=7), single ventricle physiology (n=2), among others. The majority (71.3%) of patients had trialed at least one antiarrhythmic drug. Forty-six patients (22.1%) had reduced systemic ventricular ejection fraction Conclusions: AF ablation in CHD was safe and resulted in AF control in a majority of patients, regardless of complexity. Future work should address the most appropriate ablation targets in this challenging population.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.